Kuehn Law Encourages MORF, AMBC, INFN, and BEST Investors to Contact Law Firm
10. Juli 2024 08:03 ET
|
KUEHN LAW, PLLC
Kuehn Law Encourages MORF, AMBC, INFN, and BEST Investors to Contact Law Firm
MORF REMINDER: Robbins LLP is Investigating the Officers and Directors of Morphic Holdings, Inc.
07. Dezember 2023 13:23 ET
|
Robbins LLP
MORF REMINDER: Robbins LLP is Investigating the Officers and Directors of Morphic Holdings, Inc
MORF SHAREHOLDERS: Investors of Morphic Holdings, Inc. Should Contact Robbins LLP for Information About Our Investigation
27. November 2023 18:52 ET
|
Robbins LLP
Investors of Morphic Holdings, Inc. Should Contact Robbins LLP for Information About Our Investigation
Morphic Holding, Inc. Investors Should Contact Robbins LLP for Information About Our Investigation of MORF
21. November 2023 16:11 ET
|
Robbins LLP
Morphic Holding, Inc. Investors Should Contact Robbins LLP for Information About Our Investigation of MORF
Morphic to Present at November Investor Conferences
10. November 2023 08:00 ET
|
Morphic Therapeutic
WALTHAM, Mass., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic Corporation: Company Investigated by the Portnoy Law Firm
06. November 2023 16:24 ET
|
Portnoy Law
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Nov. 06, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Morphic Holding, Inc....
Morphic Announces Participation in 2023 Wells Fargo Healthcare Conference
29. August 2023 08:00 ET
|
Morphic Therapeutic
WALTHAM, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic Announces Corporate Highlights and Financial Results for the Second Quarter 2023
03. August 2023 07:05 ET
|
Morphic Therapeutic
-Reported positive topline results from EMERALD-1 study of MORF-057 in ulcerative colitis- -Continued enrollment on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis- -Greater...
Morphic to Present at the Jefferies Global Healthcare Conference
06. Juni 2023 16:05 ET
|
Morphic Therapeutic
WALTHAM, Mass., June 06, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic Therapeutic Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
05. Mai 2023 10:30 ET
|
Morphic Therapeutic
WALTHAM, Mass., May 05, 2023 (GLOBE NEWSWIRE) -- Morphic Holding, Inc. (“Morphic”), a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious chronic...